Business
Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner
WEST HILLS, Calif., February 26, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection.
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/51df0c14fb4dfa509348f4dae65a4c99"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UvHVQOTwicwzFDjTFmwyeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/51df0c14fb4dfa509348f4dae65a4c99","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7.lTEEpg2X22Ai3m26b2gA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/51df0c14fb4dfa509348f4dae65a4c99","width":1200,"height":257}},"lazy":false},{"type":"text","content":"TacroType™ Pharmacogenetic Test designed to support more personalized tacrolimus dosing, assisting clinical decision-making in solid organ transplant recipients","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"WEST HILLS, Calif., February 26, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection.","length":377,"tagName":"p"},{"type":"text","content":"For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may reject the new organ. If it is too high, patients face increased risks of injury, infection and other serious complications. Yet patients process tacrolimus differently based in part on their genetics, making standard dosing approaches difficult and often leading to repeated adjustments during the most vulnerable period after transplant.","length":480,"tagName":"p"},{"type":"text","content":"Thermo Fisher’s new TacroType Pharmacogenetic Test provides genetic insights that can help clinicians better understand how an individual patient is likely to metabolize tacrolimus—supporting more informed dosing decisions from the start and helping reduce the trial-and-error approach that many patients experience today.","length":322,"tagName":"p"},{"type":"text","content":"The new test addresses this challenge by providing...